ArticleFrontiers in endocrinology2025
Nontargeted and targeted metabolic profile of metabolic syndrome patients: a study based on Yi and Han populations in Yunnan.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ultra-high-performance liquid chromatography-time-of-flight mass spectrometry (UHPLC-TOF-MS) was employed to analyze serum metabolites and metabolic pathways associated with metabolic syndrome (MS) in the Yi and Han populations of Yunnan. Methods: Participants included individuals diagnosed with MS and healthy controls from the Yi and Han populations of Yunnan. Serum nontargeted and amino acid-targeted metabolomics analyses were conducted to identify differential serum metabolites (DEMs) and metabolic pathways associated with MS pathogenesis in these two ethnic groups. Results: Nontargeted metabolomics analysis revealed 2,762 DEMs in the MS group of the Han population, while 1,535 DEMs were identified in the MS group of the Yi population [variable importance in projection (VIP)>1, Conclusion: Our study investigates metabolic differences in metabolic syndrome (MS) between Yi and Han populations through nontargeted and targeted metabolomics approaches, identifying both common and unique metabolites and metabolic pathways associated with MS, especially amino acid metabolic disorders, including glycine, serine, and threonine metabolism, D-glutamine and D-glutamate metabolism, which may play critical roles in regulating different metabolic dysfunctions and worth further exploration in MS pathogenesis, which might provide insights for the effective prevention and treatment of MS in various populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.